Compare NEOG & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEOG | XNCR |
|---|---|---|
| Founded | 1981 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.0B |
| IPO Year | 1995 | 2013 |
| Metric | NEOG | XNCR |
|---|---|---|
| Price | $12.30 | $23.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $10.67 | ★ $22.33 |
| AVG Volume (30 Days) | ★ 1.7M | 1.3M |
| Earning Date | 04-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.20 | 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $870,400,000.00 | $125,576,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.80 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $4.90 | $8.49 |
| 52 Week High | $12.85 | $30.61 |
| Indicator | NEOG | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 59.34 | 49.04 |
| Support Level | $11.37 | $11.20 |
| Resistance Level | $12.26 | $30.61 |
| Average True Range (ATR) | 0.38 | 1.45 |
| MACD | -0.05 | -0.70 |
| Stochastic Oscillator | 58.59 | 9.93 |
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.